Torrent Pharmaceuticals Ltd
NSE: TORNTPHARM BSE: 500420
₹4155.20
(1.48%)
Wed, 15 Apr 2026, 05:44 pm
Market Cap1385.25B
PE Ratio61.90
Dividend0.86
Health Technology
Pharmaceuticals: Major
24.5KTorrent Pharmaceuticals Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (3.6x coverage).
- Dividends after 3 years are expected to be well covered by earnings (3x coverage).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Torrent Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Torrent Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for Torrent Pharmaceuticals is expected to increase by more than 50% in 2 years time.
- Torrent Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Torrent Pharmaceuticals's earnings are expected to increase by more than the low risk growth rate in 3 years time.
- Torrent Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in Torrent Pharmaceuticals's performance (ROE) is expected over the next 3 years.
- Torrent Pharmaceuticals's revenue growth is expected to exceed the India market average.
- Torrent Pharmaceuticals's earnings are expected to grow by 16.6% yearly, however this is not considered high growth (20% yearly).
- Torrent Pharmaceuticals's earnings growth is positive but not above the India market average.
- Torrent Pharmaceuticals's earnings are expected to increase but not above the low risk growth rate next year.
- Torrent Pharmaceuticals's net income is expected to increase but not above the 50% threshold in 2 years time.
- Torrent Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Torrent Pharmaceuticals's revenue is expected to grow by 9.1% yearly, however this is not considered high growth (20% yearly).
health
- Torrent Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Torrent Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (22.6%, greater than 20% of total debt).
- Torrent Pharmaceuticals's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 3.4x coverage).
- Torrent Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Debt is not covered by short term assets, assets are 0.8x debt.
- The level of debt compared to net worth has increased over the past 5 years (110.5% vs 127.5% today).
- Torrent Pharmaceuticals's level of debt (127.5%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Torrent Pharmaceuticals board of directors is about average.
- Samir's compensation has been consistent with company performance over the past year, both up more than 20%.
- Samir's remuneration is higher than average for companies of similar size in India.
misc
- Torrent Pharmaceuticals has significant price volatility in the past 3 months.
past
- Torrent Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (134.6% vs -16.6%)
- Torrent Pharmaceuticals used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Torrent Pharmaceuticals has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Torrent Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (134.6% vs 22.7%).
- Torrent Pharmaceuticals's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Whilst Torrent Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
value
- TORNTPHARM outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- TORNTPHARM outperformed the Market in India which returned -14.5% over the past year.
- Torrent Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Torrent Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Torrent Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Torrent Pharmaceuticals is poor value based on expected growth next year.
- Torrent Pharmaceuticals is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Torrent Pharmaceuticals is overvalued based on earnings compared to the India market.
- NSEI:TORNTPHARM is up 1.5% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:TORNTPHARM is up 1.5% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800